Search for Terms or Answers
Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.
Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by speci
Dr. Richard Furie, MD, of Northwell Health in New York, presented the findings ofa large phase III trial of abatacept (Orencia) in lupus nephritis showing the agent failed to achieve a complete renal response.
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).
"Can stresss be the cause of my autoimmune disease?" is an often launched question met with shrugs of uncertainty or strongly held beliefs rooted in bias moreso than fact.
Swedish investigators have analyzed a large registry cohort and shown that exposure to stress-related disorders yields a significantly increased risk of autoimmune disease. They analyzed 106,464 patients with stress-related disorders, with 126,652 full siblings, and over a million non-stressed matched controls to assess a future risk of autoimmune disease.
A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).
MMWR reports that approximately 46 million persons (14%) in the United States live in nonmetropolitan counties, where there is a higher prevalence of obesity-associated chronic diseases such as diabetes, coronary heart disease, and arthritis.
Obese knee osteoarthritis (OA) patients who lose > 20% of their weight were in significantly less pain, had better function and improved quality of life.
The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters. In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports.
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
You can also listen on iTunes, Soundcloud or Stitcher.
Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).
We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
